Under the partnership, biopharmaceutical firms in China will get access to Guardant Health's portfolio of cancer tests to advance their clinical trial and drug development initiatives


Guardant, Adicon partner to speed up cancer therapies development in China. (Credit: Michal Jarmoluk from Pixabay)

Precision oncology company Guardant Health has partnered with Chinese clinical laboratory firm Adicon Holdings to offer Guardant’s genomic profiling tests to expedite the development of new cancer therapies in China.

Under the collaboration, Adicon will gain access to Guardant’s liquid biopsy technology, including the Guardant360 and GuardantOMNI tests, and the Guardant360 TissueNext tissue-based biopsy for patients with any solid cancerous tumour.

The tests facilitate patient screening and clinical trial enrolment and identify patients whose cancers have the appropriate molecular profiles for the researchers’ clinical programmes.

They also provide information on patient response, tumour evolution, and resistance in addition to streamlining patient screening.

As part of the partnership, biopharmaceutical firms will get access to Guardant Reveal, the first blood-only test for cancer recurrence monitoring and residual disease detection, for early-stage cancer research and development.

Guardant Health co-CEO Helmy Eltoukhy said: “Our partnership with Adicon marks another important milestone for Guardant Health, and we are excited to bring our comprehensive genomic profiling tests and services to researchers in China.

“With Adicon’s extensive expertise in clinical laboratory services, we believe they are the ideal partner to help biopharmaceutical companies bring the next generation of cancer therapies to patients in the region.”

Adicon Holdings chairwoman Ling Yang said: “We are very excited to be partnering with Guardant Health, a global leader in CGP testing, to bring a world-class testing platform to China.

“It transforms Adicon’s ability to serve biopharmaceutical customers and beyond.

“We are very committed to working with Guardant, our customers, as well as other stakeholders to bring the best novel therapies to Chinese patients.”

Guardant Health’s screening portfolio includes the commercially launched Shield test, which aims to address the needs of individuals eligible for cancer screening.

In April this year, the company partnered with Epic to integrate its broad portfolio of cancer tests with the Epic system.